Targeted genetic engineering of B cells to induce protective antibody responses to pathogens

PROJECT SUMMARY / ABSTRACT
In the United States alone, respiratory viral pathogenic infections such as influenza cause millions of
provider visits and tens of thousands of work days lost, hundreds of thousands of hospitalizations and
deaths. According to the World Health Organization, the number of viral pathogenic infections continues
to rise with higher mortalities in resource limited countries. While a successful vaccine strategy is highly
desirable, this approach relies on the induction of B cells to produce protective antibodies that either
prevent viruses from entering cells or target infected cells for destruction. Unfortunately, successful
vaccines for many viruses are not yet available after decades of research such a respiratory syncytial
virus (RSV). In this proposal, we leverage a novel approach developed by Dr. Justin Taylor’s laboratory
to genetically engineer B cells to express antibodies protective against respiratory viruses including
RSV and influenza. This strategy has already been shown to result in the production of protective
antibodies against influenza, RSV, and human immunodeficiency virus infection [Moffett et al., Science
Immunology, 2019]. While this approach can ensure protective antibody production, the genetic
engineering process required 10 days of complicated ex vivo manufacturing and is not broadly
distributable. To overcome these barriers, we will co-opt a novel, synthetic nanoparticle that was
developed in Dr. Jennifer Adair’s laboratory to deliver genetic engineering in a single, passive step
[Shahbazi et al., Nature Materials, 2019]. We show that this nanoparticle can be assembled to
genetically engineer primary human blood cells in less than 2 days, and can be modified to specifically
interact with target blood cell types in vivo. Here we will develop this scalable nanoformulation as a
vaccine-like in vivo delivery system to direct immune responses against respiratory viruses such as
RSV. We will use these nanoparticles to directly genetically engineer the most protective primary B cell
subtypes, and hematopoietic stem and progenitor cells, which can provide lifelong replenishment of
protective B cells and antibodies. This research will not only develop a unique tool set against viral
pathogens, but will provide transformative advances in equitable distribution of gene editing therapies.

Grant Number: 7R01AI158728-04
NIH Institute/Center: NIH
Principal Investigator: Jennifer Adair